d thus enhance the hypotensive effects of angiotensin II receptor antagonists. Lower initial doses or slower dose titration of risperidone may be necessary in patients receiving angiotensin II receptor antagonists concomitantly.
Ritonavir: Valsartan is a substrate of the hepatic efflux transporter MRP2 and ritonavir is an inhibitor of MRP2. Coadministration may increase systemic exposure to valsartan. Patients should be monitored for adverse effects of valsartan during coadministration.
Rituximab: Patients should not take antihypertensive agents 12 hours prior to rituximab infusions due to the possibility of hypotension occurring during the rituximab infusion.
Ropivacaine: Local anesthetics may cause additive hypotension in combination with antihypertensive agents. Thus, patients receiving antihypertensive agents may experience additive hypotensive effects.
Saxagliptin: Angiotensin II receptor antagonists (ARB) may enhance the hypoglycemic effects of saxagliptin by improving insulin sensitivity. In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in the development of new-onset diabetes in patients with hypertension or other cardiac disease. Patients receiving an ARB in combination with saxagliptin should be monitored for changes in glycemic control.
Selegiline, Transdermal: Additive hypotensive effects may be seen when selegiline is combined with angiotensin II receptor antagonists. Careful monitoring of blood pressure is suggested during coadministration. Patients should be instructed to rise slowly from a sitting position, and to report syncope or changes in blood pressure or heart rate to their health care provider.
Selegiline: Additive hypotensive effects may be seen when selegiline is combined with angiotensin II receptor antagonists. Careful monitoring of blood pressure is suggested during coadministration. Patients should be instructed to rise slowly from a sitting position, and to report syncope or changes in blood pressure or heart rate to their health care provider.
Sevoflurane: General anesthetics can potentiate the hypotensive effects of antihypertensive agents.
Sibutramine: Sibutramine may raise blood pressure or heart rate. Patients who are controlled on antihypertensive agents should be monitored for changes in blood pressure while taking sibutramine.
Silodosin: During clinical trials with silodosin, the incidence of dizziness and orthostatic hypotension was higher in patients receiving concomitant antihypertensive treatment. Thus, caution is advisable when silodosin is administered with antihypertensive agents.
Simeprevir: Concomitant use of simeprevir and valsartan may result in increased valsartan plasma concentrations and side effects. Valsartan is metabolized by OATP1B1 in vitro and simeprevir is a OATP1B1 inhibitor. Monitor patients for adverse events such as hypotension, headache, and dizziness.
Simvastatin; Sitagliptin: Angiotensin II receptor antagonists (ARB) may enhance the hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in the development of new-onset diabetes in patients with hypertension or other cardiac disease. Patients receiving an ARB in combination with antidiabetic agents should be monitored for changes in glycemic control.
Sitagliptin: Angiotensin II receptor antagonists |
